AMNEAL PHARMACEUTICALS, INC. Acquisitions, Net of Cash Acquired
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Acquisitions, Net of Cash Acquired of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired · last filed 2025-02-28
- AMNEAL PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2022-09-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2021-12-31 was $72.72M.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for the quarter ending 2021-09-30 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2024 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2022 was $84.71M, a 42.19% decline from fiscal 2021.
- AMNEAL PHARMACEUTICALS, INC. payments to acquire businesses, net of cash acquired for fiscal 2021 was $146.54M, a 41.70% decline from fiscal 2020.
| Period end | Payments to Acquire Businesses, Net of Cash Acquired 3 month | Payments to Acquire Businesses, Net of Cash Acquired 6 month | Payments to Acquire Businesses, Net of Cash Acquired 9 month | Payments to Acquire Businesses, Net of Cash Acquired 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-28 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-02-28 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $84.71M 10-K · filed 2025-02-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $84.71M 10-Q · filed 2022-11-07 | ||
| 2022-06-30 | $84.71M 10-Q · filed 2022-08-08 | |||
| 2021-12-31 | $72.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $72.72M derived: sum of 2 quarters · filed 2024-03-14 | $146.54M derived: sum of 3 quarters · filed 2024-03-14 | $146.54M 10-K · filed 2024-03-14 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $73.83M derived: sum of 2 quarters · filed 2022-11-07 | $73.83M 10-Q · filed 2022-11-07 | $73.83M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $73.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $73.83M 10-Q · filed 2022-08-08 | $73.83M derived: sum of 3 quarters · filed 2023-03-03 | $71.19M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-07 | $0.00 derived: sum of 2 quarters · filed 2023-03-03 | -$2.64M derived: sum of 3 quarters · filed 2023-03-03 | -$2.27M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | -$2.64M derived: sum of 2 quarters · filed 2023-03-03 | -$2.27M derived: sum of 3 quarters · filed 2023-03-03 | $251.36M 10-K · filed 2023-03-03 |
| 2020-09-30 | -$2.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$2.27M derived: sum of 2 quarters · filed 2021-11-08 | $251.36M 10-Q · filed 2021-11-08 | $251.36M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $375.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $254.00M 10-Q · filed 2021-08-09 | $254.00M derived: sum of 3 quarters · filed 2022-03-01 | $254.00M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $253.63M 10-Q · filed 2021-05-07 | $253.63M derived: sum of 2 quarters · filed 2022-03-01 | $253.63M derived: sum of 3 quarters · filed 2022-03-01 | $253.63M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $0.00 derived: sum of 2 quarters · filed 2022-03-01 | $0.00 derived: sum of 3 quarters · filed 2022-03-01 | $0.00 10-K · filed 2022-03-01 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $0.00 derived: sum of 2 quarters · filed 2020-11-06 | $0.00 10-Q · filed 2020-11-06 | $0.00 derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | $0.00 derived: sum of 3 quarters · filed 2021-03-01 | $3.31M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $0.00 10-Q · filed 2020-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $3.31M derived: sum of 3 quarters · filed 2021-03-01 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $3.31M derived: sum of 2 quarters · filed 2021-03-01 | $324.63M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $3.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $324.63M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $321.32M 10-Q · filed 2019-08-05 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $0.00 derived: sum of 2 quarters · filed 2020-03-02 | $0.00 10-K · filed 2020-03-02 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |